The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Ibrance

125 milligram(s) Capsule, hard

Pfizer Europe MA EEIGEU/1/16/1147/005-006

Main Information

Trade NameIbrance
Active SubstancesPalbociclib
Strength125 milligram(s)
Dosage FormCapsule, hard
Licence HolderPfizer Europe MA EEIG
Licence NumberEU/1/16/1147/005-006

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE33 palbociclib

Status

Authorised/WithdrawnAuthorised
Licence Issued09/11/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back